{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:44:17Z","timestamp":1782895457561,"version":"3.54.5"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Allogeneic hematopoietic stem cell transplantation (HSCT) has markedly improved survival in children with primary immunodeficiencies (PIDs) transforming previously fatal diseases into curable conditions. As survival improves late effects are emerging as major concerns. We performed a systematic review aiming to identify, categorize, and summarize late effects (LEs) following allogeneic HSCT in pediatric patients with PIDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA guidelines, PubMed and EBSCOhost databases were searched without date restrictions for studies reporting LEs in patients who underwent allogeneic HSCT for PIDs at the age of 0\u201317 years and survived at least 2 years after HSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1,142 screened publications, 31 met the inclusion criteria, including 2,293 patients transplanted from 1981 to 2019 and followed for long-term outcomes. The main indications included severe combined immunodeficiency, Wiskott-Aldrich Syndrome (WAS), chronic granulomatous disease, leukocyte adhesion deficiency, and other rare PIDs. At least one LE was reported in 544 out of 2,293 patients (24%) who were followed up from 2 to 38 years. Growth and developmental delay were the most frequently reported LEs, observed in at least 280 patients (12.2%). This was followed by neurological (n=173, 7.5%) and autoimmune or hematologic (n=161, 7.0%) long-term issues. Pulmonary and skin complications were noted in 150 patients each (6.5% each), while dental and skeletal impairments affected 112 patients (4.9%). Endocrine issues were reported in 99 patients (4.3%), and gastrointestinal or liver impairments occurred in 75 patients (3.3%). Secondary malignancies, renal\/metabolic, recurrent infections, hearing loss, ocular and vascular late complications were rare and reported in less than 1% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A substantial proportion of pediatric HSCT survivors with PIDs experience LEs. They affect various organs and systems years after an immune system replacement. These findings highlight the need for lifelong, multidisciplinary follow-up to optimize long-term health, functional outcomes, and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024621972<\/jats:ext-link>\n                      , identifier CRD42024621972.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1752700","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:48:47Z","timestamp":1782892127000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Late effects after allogeneic hematopoietic stem cell transplantation in patients with primary immunodeficiency"],"prefix":"10.3389","volume":"17","author":[{"given":"Gint\u0117","family":"Grubliauskait\u0117","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Vilnius University","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audron\u0117","family":"Mulevi\u010dien\u0117","sequence":"additional","affiliation":[{"name":"Center for Pediatric Oncology and Hematology, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Rascon","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Vilnius University","place":["Vilnius, Lithuania"]},{"name":"Center for Pediatric Oncology and Hematology, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02524-2","article-title":"The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid Malignancies and of CAR-T at the expense of autologous HCT","volume":"60","author":"Passweg","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250003","article-title":"Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"1","author":"Poli","year":"2025","journal-title":"J Hum Immun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00895-3","article-title":"Outcome of non-hematological autoimmunity after hematopoietic cell transplantation in children with primary immunodeficiency","volume":"41","author":"Lum","year":"2021","journal-title":"J ClinImmunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704456","article-title":"Thyroid dysfunction after bone marrow transplantation for primary immunodeficiency without the use of total body irradiation in conditioning","volume":"33","author":"Slatter","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702831","article-title":"Bone marrow transplantation for T-B- severe combined immunodeficiency disease in Athabascan-speaking native Americans","volume":"27","author":"O\u2019Marcaigh","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01755-x","article-title":"Late endocrine effects after hematopoietic stem cell transplantation in children with nonmalignant diseases","volume":"57","author":"de Kloet","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.09.027","article-title":"Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study","volume":"153","author":"Eissa","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.08.007","article-title":"Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency","volume":"120","author":"Mazzolari","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01465-z","article-title":"Non-osteopenic bone pathology after allo-hematopoietic stem cell transplantation in patients with inborn errors of immunity","volume":"43","author":"Golwala","year":"2023","journal-title":"J ClinImmunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.62021","article-title":"Chondrodysplasia and growth failure in children after early hematopoietic stem cell transplantation for non-oncologic disorders","volume":"185","author":"Botto","year":"2021","journal-title":"Am J Med Genet Part A"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01112-5","article-title":"Hematopoietic cell transplantation for severe combined immunodeficiency patients: a Japanese retrospective study","volume":"41","author":"Miyamoto","year":"2021","journal-title":"J ClinImmunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0316-z","article-title":"Long-term outcomes of hematopoietic stem cell transplantation for ZAP70 deficiency","volume":"36","author":"Cuvelier","year":"2016","journal-title":"J ClinImmunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jpeds.2009.07.049","article-title":"Long term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pre-transplant chemotherapy or post-transplant GVHD prophylaxis","volume":"155","author":"Railey","year":"2009","journal-title":"J Pediatr"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2022.03.012","article-title":"Assessing long-term effects after stem cell transplantation: design of the MOSA study","volume":"148","author":"Wauben","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.10.030","article-title":"Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb","volume":"122","author":"Patel","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jaip.2021.12.018","article-title":"Long-term clinical outcomes of severe combined immunodeficiency patients given nonablative marrow transplants","volume":"10","author":"Hardin","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-034678","article-title":"Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications","volume":"109","author":"H\u00f6nig","year":"2007","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2011.01491.x","article-title":"Two SCID cases with Cernunnos-XLF deficiency successfully treated by hematopoietic stem cell transplantation","volume":"16","author":"\u00c7a\u011fda\u015f","year":"2012","journal-title":"Pediatr Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-004-1742-3","article-title":"Granulomatous interstitial nephritis associated with bone marrow transplantation","volume":"20","author":"Schwaderer","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1229674","article-title":"Rare solid tumors in a patient with Wiskott\u2013Aldrich syndrome after hematopoietic stem cell transplantation: case report and review of literature","volume":"14","author":"Coppola","year":"2023","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.jaci.2009.08.041","article-title":"Outcomes of severe combined immunodeficiency patients treated with hematopoietic stem cell transplantation with and without pre-conditioning","volume":"124","author":"Patel","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-748616","article-title":"Long-term outcome of hematopoietic stem cell transplantation for IL2RG\/JAK3 SCID: a cohort report","volume":"129","author":"Abd Hamid","year":"2017","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-018-0540-9","article-title":"Long-term health outcome and quality of life post-HSCT for IL7R\u03b1-, Artemis-, RAG1- and RAG2-deficient severe combined immunodeficiency: a single center report","volume":"38","author":"Abd Hamid","year":"2018","journal-title":"J ClinImmunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-008-9250-z","article-title":"Long-term neurocognitive function of pediatric patients with severe combined immune deficiency (SCID): pre- and post-hematopoietic stem cell transplant (HSCT)","volume":"29","author":"Lin","year":"2009","journal-title":"J ClinImmunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705017","article-title":"Hematopoietic stem cell transplantation in Omenn syndrome: a single-center experience","volume":"36","author":"Mazzolari","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"B27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12026-008-8067-4","article-title":"Matched unrelated bone marrow transplant for Omenn syndrome","volume":"44","author":"Nahum","year":"2009","journal-title":"Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.11","article-title":"Matched unrelated bone marrow transplant for T+ combined immunodeficiency","volume":"41","author":"Roifman","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.5.508","article-title":"Bone marrow transplantation for severe combined immune deficiency","volume":"295","author":"Grunebaum","year":"2006","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1399-3046.2011.01606.x","article-title":"A single\u2010center study of hematopoietic stem cell transplantation for primary immune deficiencies (PIDD)","volume":"16","author":"DiNardo","year":"2012","journal-title":"Pediatr Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12967","article-title":"Effect of reduced-intensity conditioning and the risk of late-onset non-infectious pulmonary complications in pediatric patients","volume":"99","author":"Nagasawa","year":"2017","journal-title":"Eur J Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177923","article-title":"Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency","volume":"113","author":"Neven","year":"2009","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12026-008-8022-4","article-title":"Single-center analysis of long-term outcome after hematopoietic cell transplantation in children with congenital severe T cell immunodeficiency","volume":"44","author":"Mazzolari","year":"2009","journal-title":"Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-017-0421-7","article-title":"Long-term outcome of adenosine deaminase-deficient patients\u2014a single-center experience","volume":"37","author":"Scott","year":"2017","journal-title":"J ClinImmunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)02178-7","article-title":"Toxicities of total-body irradiation for pediatric bone marrow transplantation","volume":"34","author":"Chou","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B36","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/1744666X.2022.2072299","article-title":"Autoimmune diseases after allogeneic stem cell transplantation: a clinician\u2019s guide and outlook","volume":"18","author":"Faraci","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109142","article-title":"Transplantation to save the life, TSH screening to save the brain: a report and brief literature review of autoimmune thyroid disease after HSCT for severe combined immunodeficiency","volume":"245","author":"Baccelli","year":"2022","journal-title":"Clin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.09.014","article-title":"Late effects after hematopoietic stem cell transplantation in patients with HLH: a Histiocyte Society, PDWP, IEWP, and TCWP EBMT study","volume":"157","author":"Ramme","year":"2026","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608653","article-title":"Immune reconstitution after gene therapy approaches in patients with X-linked severe combined immunodeficiency disease","volume":"11","author":"Blanco","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1752700\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:48:48Z","timestamp":1782892128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1752700\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1752700"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1752700","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1752700"}}